Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience

Jeffrey A. Berinstein*, Taylor Karl, Anish Patel, Michael Dolinger, Terrence A. Barrett, Waseem Ahmed, Ben Click, Calen A. Steiner, David Dulaney, Jake Levine, Syed Adeel Hassan, Courtney Perry, Deborah Flomenhoft, Ryan C. Ungaro, Elliot M. Berinstein, Jessica Sheehan, Shirley Cohen-Mekelburg, Randolph E. Regal, Ryan W. Stidham, Shrinivas BishuJean Frederic Colombel, Peter D.R. Higgins

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy. METHODS: Patients with ASUC treated with upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions. RESULTS: Of the 25 patients with ASUC treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) of the 18 patients with available data and who did not undergo colectomy experienced steroid-free clinical remission (1 patient did not have complete data), 1 (4%) patient experienced a venous thromboembolic event, while 5 (20%) patients were readmitted. DISCUSSION: Upadacitinib along with intravenous corticosteroids may be an effective treatment for ASUC.

Original languageEnglish
Pages (from-to)1421-1425
Number of pages5
JournalAmerican Journal of Gastroenterology
Volume119
Issue number7
DOIs
StatePublished - 1 Jul 2024
Externally publishedYes

Keywords

  • Janus kinase inhibitors
  • acute severe ulcerative colitis
  • ulcerative colitis
  • upadacitinib

Fingerprint

Dive into the research topics of 'Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience'. Together they form a unique fingerprint.

Cite this